Table 2 Probability of events following the first hospitalization and number of events
RSV-hospitalized subjects | Subjects without RSV-hospitalization | |||||
|---|---|---|---|---|---|---|
Probability of occurrence | 33–35 wks | < 33 wks | BPD | 33–35 wks | < 33 wks | BPD |
Probability of events following the first hospitalization | ||||||
- hospitalization during the first 12 months after enrolment | 100.0% | 100.0% | 100.0% | 60.0% | 60.0% | 60.0% |
- mortality throughout the first 12 months | 4.0% | 4.0% | 4.0% | 0.8% | 0.8% | 0.8% |
- probability of developing recurrent wheezing throughout the 24 months following enrolment with palivizumab [14] | 17.0%* | 17.0%* | 17.0%* | 8.0% | 8.0% | 8.0% |
- probability of developing recurrent wheezing throughout the 24 months following enrolment without palivizumab [14] | 17.0% | 17.0% | 17.0% | 16.0% | 16.0% | 16.0% |
Events | ||||||
- no. of hospitalizations due to respiratory causes during the first 12 months after enrollment | 2.89 | 5.40 | 5.40 | 1.28 | 1.00 | 1.00 |